Skip to content
Use your HSA or FSA funds

Condition report · Metabolic

Gaucher Disease

Whole genome sequencing identifies GBA variants that cause lysosomal accumulation, enabling enzyme replacement or substrate reduction therapy tailored to your genetic subtype.

A condition report looks for rare variants known to cause the conditions it covers.

Included with every kit

From $449Free shipping · Results in 6–8 weeks

Get my Genome Test

About this condition

An inherited lysosomal storage disorder caused by variants in the GBA1 gene, in which a fatty substance (glucocerebroside) builds up, mainly in the spleen, liver and bone marrow. Type 1 is the most common; types 2 and 3 also affect the brain.

Gaucher disease is an autosomal recessive lysosomal storage disorder caused by GBA mutations, which encode glucocerebrosidase, the enzyme that breaks down glucocerebroside into glucose and ceramide. Loss-of-function GBA variants impair this breakdown, causing glucocerebroside to accumulate in macrophages and other cells, creating characteristic lipid-laden Gaucher cells. The disease manifests in three clinical types: Type 1 (non-neuronopathic, ~95% of cases) features hepatosplenomegaly, anemia, thrombocytopenia, and progressive bone disease; Type 2 (acute neuronopathic, rare) is fatal by age 2-4; and Type 3 (chronic neuronopathic) shows progressive neurological decline alongside organ involvement.

Gaucher disease affects approximately 1 in 40,000 to 1 in 60,000 individuals globally, though prevalence is dramatically higher in Ashkenazi Jewish populations (~1 in 850). Over 400 GBA variants have been identified. Four Ashkenazi founder mutations (N370S, 84GG, L444P, and IVS2+1G>A) account for approximately 96% of alleles in that population. Genotype predicts severity: Type 1 (non-neuronopathic) variants typically retain residual enzyme activity (~10-30%), while Type 2/3 (neuronopathic) variants reduce activity more profoundly or produce misfolded enzyme. Interestingly, heterozygous GBA carriers (approximately 1-3% of the general population) have a 5- to 10-fold increased risk of Parkinson's disease, revealing an unexpected link between lysosomal dysfunction and neurodegeneration.

A confirmed GBA pathogenic variant diagnosis enables enzyme replacement therapy (imiglucerase, velaglucerase alfa) or substrate reduction therapy (eliglustat for Type 1, miglustat for Types 1 and 3), both FDA-approved and directly targeting the molecular consequence of GBA loss. Type 1 (non-neuronopathic) variants typically respond well, with therapies reducing hepatosplenomegaly, improving hematologic parameters, and halting bone disease progression. Type 2 (acute neuronopathic) does not currently have effective disease-modifying treatments. Type 3 shows variable response to enzyme replacement. Treatment efficacy correlates with genotype: N370S (milder) typically responds better than L444P (more severe). Genetic diagnosis enables early treatment initiation, preventing irreversible organ and bone complications.

GBA genotype predicts clinical type and treatment response: Type 1 variants typically respond well to enzyme replacement or substrate reduction therapy, while Type 2 remains untreatable and Type 3 shows variable response.

The condition we analyse

Autosomal recessive

Gaucher disease (GD) is a lysosomal storage disorder encompassing three main forms (types 1, 2 and 3), a fetal form and a variant with cardiac involvement (Gaucher disease - ophthalmoplegia - cardiovascular calcification or Gaucher-like disease).

What a diagnosis changes

Enzyme replacement therapy, substrate reduction therapy, supportive care, bone marrow transplantation

Genes analysed

Also known as

acid beta-glucosidase deficiency; acute cerebral Gaucher disease; Gaucher syndrome; glucocerebrosidase deficiency; glucocerebrosidosis; glucosyl cerebroside lipidosis; glucosylceramidase deficiency; glucosylceramide beta-glucosidase deficiency; lipoid histiocytosis (kerasin type); sphingolipidosis 1

Includes 5 related subtypes ↓
  • Gaucher disease perinatal lethal
  • Gaucher disease type I
  • Gaucher disease type II
  • Gaucher disease type III
  • Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome
MONDO:0018150Orphanet 355MedGen 42164

Why whole genome sequencing

GBA testing is technically challenging due to pseudogene contamination. Over 400 variants exist, and standard sequencing frequently produces ambiguous results.

GBA sequencing requires specialized techniques to distinguish true variants from pseudogene artifacts

GBA sequencing is technically challenging because the GBA gene has a pseudogene (GBAP1) on chromosome 1 that shares 96% sequence identity. Standard short-read sequencing frequently misaligns GBA and GBAP1 sequences, producing ambiguous or incorrect results. Large deletions or complex rearrangements may not be detected by exome sequencing alone. Over 400 GBA variants have been identified, many population-specific. Specialized GBA testing with careful bioinformatic annotation and long-read sequencing capabilities is essential for diagnostic accuracy. Whole genome sequencing with appropriate bioinformatic controls can capture GBA variants while controlling for pseudogene contamination.

Genotype-based treatment selection improves outcomes significantly

A confirmed GBA pathogenic variant enables enzyme replacement therapy (imiglucerase, velaglucerase alfa) or substrate reduction therapy (eliglustat, miglustat), FDA-approved drugs that directly target glucocerebroside accumulation. Treatment response correlates with genotype: Type 1 (non-neuronopathic) variants typically respond well, with rapid reduction in hepatosplenomegaly and improvement in hematologic and bone parameters. Milder variants (N370S) typically respond better than more severe variants (L444P). Early treatment initiation prevents irreversible organ and bone complications. GBA heterozygous carriers identified through cascade screening may benefit from enhanced neurological surveillance for Parkinson's disease risk.

Other metabolic conditions

All conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. Physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Free shipping · Results in 6–8 weeks

Get my Genome Test